Stonepine Capital Management
CRBP icon

Stonepine Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Stonepine Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$648K Sell
95,000
-330,000
-78% -$3.05M 0.41% 48
2026
Q2 		$3.99M Buy
425,000
+41,538
+11% +$393K 2.25% 14
2026
Q1 		$3.6M Sell
383,462
-6,454
-2% -$54.3K 1.44% 12
2025
Q4 		$3.17M Buy
+389,916
New +$4.81M 2.32% 9
2025
Q2 		– Sell
-35,000
Closed -$186K – 64
2025
Q1 		$186K Buy
+35,000
New +$309K 0.18% 52

Other funds holding CRBP

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Stonepine Capital Management's CRBP Position: Q3 2026 in Review

Stonepine Capital Management reduced its Corbus Pharmaceuticals (CRBP) stake by 78% in Q3 2026, selling an estimated $3.05M and leaving 95,000 shares worth $648K. The position accounts for 0.41% of the portfolio, ranked #48.

Stonepine Capital Management first reported a position in CRBP in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.99M in Q2 2026. 76 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

  • Stonepine Capital Management held 95,000 shares of Corbus Pharmaceuticals worth $648K as of Q3 2026.
  • Stonepine Capital Management sold 330,000 Corbus Pharmaceuticals shares in Q3 2026, an estimated $3.05M.
  • Corbus Pharmaceuticals made up 0.41% of Stonepine Capital Management's portfolio in Q3 2026, its #48 holding.
  • Stonepine Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Stonepine Capital Management's Corbus Pharmaceuticals position peaked at $3.99M in Q2 2026.
  • 76 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Stonepine Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.